Lumeda is a clinical-stage medtech company focused on improving outcomes for patients diagnosed with lung cancer based on our breakthrough DigiLum™ Photodynamic Therapy (PDT) platform. This system is designed to efficiently activate a photosensitizer drug in the thoracic cavity and deliver PDT to extend patient survival and improve their quality of life.
Lumeda was formed late 2019 by an experienced management team with a track record of creating successful new ventures. Working alongside a leading national cancer center, we are a multidisciplinary team committed to introducing new light-activated treatment modalities for cancer. We strive for technical excellence and work to the highest ethical standards.
Lumeda is targeting thoracic applications for DigiLum™ that apply PDT intraoperatively during standard of care procedures. Our lead indication is for use of DigiLum™ to extend survival of patients with late-stage lung cancer by priming the host immune system to stimulate anti-tumor immunity for an improved response to standard of care immunotherapy.